Cabozantinib Plus Nivolumab Trial Review
September 25th 2025Panelists discuss results from a phase 2 study of nivolumab plus cabozantinib in non–clear cell renal cell carcinoma, highlighting promising efficacy but notable treatment discontinuation rates likely linked to patient complexity, underscoring the need for further research on TKI-IO combinations in this diverse population.
Overview of Non–Clear Cell Renal Cell Carcinoma
September 18th 2025Panelists discuss first-line therapy for non–clear cell renal cell carcinoma, emphasizing its diverse histologies, the challenges posed by limited clinical trial data, and the importance of molecular diagnostics and multidisciplinary strategies to guide personalized treatment.
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?
September 15th 2015There is ample evidence suggesting that physical activity and exercise can be therapeutic tools for patients with prostate cancer. Patients diagnosed with localized disease should be advised to stay physically active; furthermore, patients who are undergoing radiation therapy and/or treatment with ADT appear to benefit from regular aerobic and resistance exercise to alleviate side effects.